Clinical experience with intravenous administration of ascorbic acid: Achievable levels in blood for different states of inflammation and disease in cancer patients

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Mikirova, Nina ^a   Casciari, Joseph ^a   Riordan, Neil ^a   Hunninghake, Ronald ^a  

^a Riordan Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; COLON CANCER; COLON METASTASIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; ESOPHAGUS CANCER; ESOPHAGUS METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; KIDNEY CANCER; KIDNEY METASTASIS; LUNG CANCER; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD; MELANOMA; METASTASIS POTENTIAL; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PANCREAS METASTASIS; PHARYNX CANCER; PROSTATE CANCER; RETROSPECTIVE STUDY; SARCOMA; SKIN CANCER; STOMACH CANCER; THYMUS CANCER; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME; UTERUS CANCER; BLOOD; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASMS; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ASCORBIC ACID; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881427604     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-191     Document Type: Article

References (85)

1. Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Pinnell SR. Regulation of collagen synthesis by ascorbic acid. Proc Natl Acad Sci USA 1981, 78(5):2879-2882. 10.1073/pnas.78.5.2879, 319462, 6265920.
2. Ottoboni F, Ottoboni A. Ascorbic acid and the immune system. J Orthomolecular Med 2005, 20(3):179-183.
3. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 2010, 5(7):11414.
4. Frei B, Lawson S. Vitamin C and cancer revisited. PNAC USA 2008, 105:11037-11038.
5. Padayatti SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004, 140:533-537. 10.7326/0003-4819-140-7-200404060-00010, 15068981.
6. Klenner FR. The treatment of poliomyelitis and other virus diseases with vitamin C. South Med Surg 1949, 111:209-214.
7. Klenner FR. Massive doses of vitamin C and the virus diseases. South Med Surg 1951, 113:101-107.
8. Calleja HB, Brooks RH. Acute hepatitis treated with high doses of vitamin C. Report of a case. Ohio Med 1960, 56:821-823.
9. Mikirova N, Rogers A, Casciari J, Taylor P. Effects of high dose intravenous ascorbic acid on the level of inflammation in patients with rheumatoid arthritis. Mod Res Inflamm 2012, 1:26-32.
10. McCormick W. Cancer: a collagen disease, secondary to nutrition deficiency. Arch Pediatr 1959, 76:166-171.
11. Cameron E, Pauling L, Leibovitz B. Ascorbic acid and cancer, a review. Cancer Res 1979, 39:663-681.
12. Hoffman F. Micronutrient requirements of cancer patients. Cancer 1985, 55(1):145-150.
13. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005, 24:269-276.
14. Henson D, Block G, Levine M. Ascorbic acid: biological functions and relation to cancer. JNCI 1991, 83:547-550. 10.1093/jnci/83.8.547, 1672383.
15. Fain O, Mathieu E, Thomas M. Scurvy in patients with cancer. BMJ 1998, 316:1661-1662. 1113239, 9603754.
16. Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med 2005, 19:17-20. 10.1191/0269216305pm970oa, 15690864.
17. Bodansky O, Wroblewski F, Markardt B. Concentrations of ascorbic acid in plasma and white blood cells of patients with cancer and noncancerous chronic disease. Cancer 1952, 5:678-684. 10.1002/1097-0142(195207)5:4<678::AID-CNCR2820050404>3.0.CO;2-7, 14935977.
18. Butcher RG, Chayen J. Oxidation of L-ascorbic acid by cells of carcinoma of the human cervix. Nature 1965, 207:992-993. 10.1038/207992a0, 5886944.
19. Fraenkel-Conrat J, Stoy T, Tsai SF. Investigation of ascorbic acid levels in blood of cancer patients compared to normal subjects. Mo Med 1967, 64:1001-1002.
20. Anthony HM, Schorah CJ. Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer 1982, 46:354-367. 10.1038/bjc.1982.211, 2011112, 7126425.
21. Gupta A, Bhatt ML, Misra MK. Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev 2009, 2:68-72. 10.4161/oxim.2.2.8160, 2763247, 20357927.
22. Casciari J, Riordan NS, Schmidt TL, Meng XL, Jackson J, Riordan H. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer 2001, 84(11):1544-1550. 10.1054/bjoc.2001.1814, 2363673, 11384106.
23. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005, 102:13604-13609. 10.1073/pnas.0506390102, 1224653, 16157892.
24. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008, 105:11105-11109. 10.1073/pnas.0804226105, 2516281, 18678913.
25. Verrax J, Calderon P. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009, 47:32-40. 10.1016/j.freeradbiomed.2009.02.016, 19254759.
26. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 2010, 16:509-520. 10.1158/1078-0432.CCR-09-1713, 2807999, 20068072.
27. Pollard HB, Levine MA, Eidelman O, Pollard M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In vivo 2010, 24:249-256.
28. Pollard H, Levine M, Eidelman O, Pollard M. Pharmacological ascorbic acid supresses syngenic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 2010, 24(3):249-255.
29. Ashino H, Shimamura M, Nakajima M, Kawanaka S, Oikawa T, Iwaguchi T, Kawashima S. Novel function of ascorbic acid as an angiostatic factor. Angiogenesis 2003, 6:259-269.
30. Belin S, Kaya F, Duisit G, Giacomett S, Ciccoloni J, Fortes M. Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS One 2009, 4(2):E44.
31. Page EL, Chan DA, Giaccia AJ, Levine M, Richard DE. Hypoxia-inducible factor-1 (alpha) stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2007, 19:86-94. 2174200, 17942596.
32. Mikirova N, Casciari J, Riordan N. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenesis Res 2012, 2:2-6.
33. Mikirova N, Ichim T, Riordan N. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med 2008, 6:50. 10.1186/1479-5876-6-50, 2562367, 18789157.
34. Yeom CH, Lee G, Park JH, Yu J, Park S, Yi SY, Lee HR, Hong YS, Lee S. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 2009, 7:70. 10.1186/1479-5876-7-70, 2732919, 19671184.
35. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 2008, 19(12):2095.
36. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J, Vollbracht C. Intravenous vitamin C administration improves quality of life in breast cacner patients during chemo-radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. Vivo 2011, 82:983-990.
37. Takahashi H, Mizuno H, Yanagisawa A. High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe 1 2012, 49:e53.
38. Jackson J, Riordan H, Hunninghauke R, Riordan N. High dose intravenous vitamin C and long time survival of a patient with cancer of the head and pancreas. J Ortho Med 1995, 10:87-88.
39. Riordan H, Jackson J, Riordan N, Schultz M. High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. J Ortho Med 1998, 13:72-73.
40. Riordan N, Jackson JA, Riordan H. Intravenous vitamin C in a terminal cancer patient. J Ortho Med 1996, 11:80-82.
41. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenous vitamin C as a cancer therapy: three cases. CMAJ 2006, 174(7):937-942. 10.1503/cmaj.050346, 1405876, 16567755.
42. Mikirova N, Casciari J, Taylor P, Rogers A. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med 2012, 10:189. 10.1186/1479-5876-10-189, 3480897, 22963460.
43. Drisko J, Chapman J, Hunter V. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. Am J Coll Nutr 2003, 22:118-123.
44. Riordan HD, Hunninghake RB, Riordan NH, Jackson JJ, Meng X, Taylor P, Casciari JJ, Gonzalez MJ, Miranda-Massari JR, Mora EM, Rosario N, Rivera A. Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J 2003, 22:225-232.
45. Riordan NH, Riordan HRD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Medical hypothesis 1995, 44:207-213.
46. Casciari JJ, Riordan HD, Mirranda-Massara JR, Gonzalez MJ. Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs. PR Health Sci J 2005, 24:145-150.
47. Fujita K, Shinpo K, Yamada K, Sato K, Niimi H, Shamoto M, Nagatsu T, Takeuchi T, Umezawa H. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res 1982, 42:309-316.
48. Okunieff P, Suit H. Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine firbosarcomas. JNCI 1987, 79:377-381.
49. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 1996, 103:183-189. 10.1016/0304-3835(96)04212-7, 8635156.
50. Taper H, Keyeux A, Roberfroid M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res 1996, 16:499-503.
51. Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F, Aigner A. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells toward cytostatic drugs. Cancer Chemother Pharmacol 2011, 67:1157-1166. 10.1007/s00280-010-1418-6, 3082037, 20694726.
52. Shinozaki K, Hosokawa Y, Hazawa M, Kashiwakura I, Okumura K, Kaku T, Nakayama E. Ascorbic acid enhances radiation-induced apoptosis in an HL60 human leukemia cell line. J Ratiat Res 2011, 52:229-237.
53. Espey M, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 2011, 50:1610-1619. 10.1016/j.freeradbiomed.2011.03.007, 3482496, 21402145.
54. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. PNAS USA 1976, 73:3685-3689. 10.1073/pnas.73.10.3685, 431183, 1068480.
55. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Engl J Med 1979, 301:687-690. 10.1056/NEJM197909273011303, 384241.
56. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have no prior chemotherapy: a randomized double-blind comparison. N Engl J Med 1985, 312:137-141. 10.1056/NEJM198501173120301, 3880867.
57. Simone CB, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not inferfere with chemotherapy or radiation therapy and can increase survival, part 1. Atlern Ther Health Med 2007, 13:22-28.
58. Block K, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementaion on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008, 123:1227-1239. 10.1002/ijc.23754, 18623084.
59. Ullah MF, Bhat SH, Hussain E, Abu-Duhier F, Ahmad A, Hadi SM. Ascorbic acid in cancer chemoprevention: translational perspectives and efficacy. Current drug target 2012, 13:1757-1771.
60. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996, 93:3704-3709. 10.1073/pnas.93.8.3704, 39676, 8623000.
61. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991, 51:794-798.
62. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327. 10.1186/bcr315, 138696, 11597322.
63. Sundaresan M, Yu Z-X, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ, Finkel T. Regulation of reactiveoxygen- species generation in fibroblasts by Rac1. Biochem J 1996, 318:379-382. 1217632, 8809022.
64. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995, 18:775-794. 10.1016/0891-5849(94)00198-S, 7750801.
65. Wang X, Martindale JL, Liu Y, Holbrook NJ. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 1998, 333:291-300. 1219585, 9657968.
66. Huot J, Houle F, Marceau F, Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 1997, 80:383-392. 10.1161/01.RES.80.3.383, 9048659.
67. Dakubo GD. The Warburg phenomenon and other metabolic alterations of cancer cells. In Mitochondrial genetics and cancer 2010, 39-66. Berlin Heidelberg: Springer-Verlag.
68. Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 1999, 59(18):4555-4558.
69. Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol 2010, 2010:1-4. (article ID 205357).
70. Jennifer L, St Sauver AV, Sarma DJ, Jacobson ME, McGree MM, Lieber CJ, Girman AN, Jacobsen SJ. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 2009, 169:1281-1290. 10.1093/aje/kwp085, 2727252, 19395697.
71. Lin ATL, Chen KK, Chung HJ, Chang SC. The significance of plasma C-reactive protein in patients with elevated serum prostate-specific antigen levels. Urological Science 2010, 21(2):88-92.
72. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
73. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217. 10.1016/j.ccr.2005.02.013, 15766659.
74. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003, 3:276-285. 10.1038/nrc1046, 12671666.
75. Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006, 391:499-510. 10.1007/s00423-006-0073-1, 16909291.
76. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37. 10.1038/nrc1782, 16397525.
77. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121:2373-2380. 10.1002/ijc.23173, 17893866.
78. Haitian L, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006, 4:221-233. 10.1158/1541-7786.MCR-05-0261, 16603636.
79. Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer. II. Role of chronic inflammation and cytokine polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004, 286:G515-G520. 10.1152/ajpgi.00475.2003, 15010360.
80. Dunn G, Bruce A, Ikeda H, Old L, Schreiber R. Cancer immune-editing: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998. 10.1038/ni1102-991, 12407406.
81. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes?. Clin Exp Metastasis 2002, 19:247-258. 10.1023/A:1015587423262, 12067205.
82. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6:149-163. Review, 10.2217/fon.09.136, 20021215.
83. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009, 12:223-226. Review, 10.1097/MCO.0b013e32832a7902, 19318937.
84. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 2010, 87:504-508. 10.1038/clpt.2009.254, 20147899.
85. Marsik C, Kazemi-Shirazi L, Schickbauer T, et al. C-reactive protein and all-cause mortality in large hospital-based cohort. Clin Chem 2008, 54:343-349. 10.1373/clinchem.2007.091959, 18156283.